selegiline

Summary

Summary: A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.

Top Publications

  1. ncbi Neuroprotective actions of selegiline
    M Ebadi
    Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58203, USA
    J Neurosci Res 67:285-9. 2002
  2. ncbi Selegiline and oxidative stress in HIV-associated cognitive impairment
    G Schifitto
    University of Rochester, NY, USA
    Neurology 73:1975-81. 2009
  3. ncbi A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition
    A Clarke
    Scherer DDS, Swindon, United Kingdom
    J Neural Transm 110:1257-71. 2003
  4. ncbi Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline
    A Kupsch
    Department of Neurology, Klinikum Grosshadern, Ludwig Maximilians University, and Institute of Physiology, Munchen, Federal Republic of Germany
    J Neural Transm 108:985-1009. 2001
  5. ncbi Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline
    Orit Bar Am
    Eve Topf and US National Parkinson Foundation Center of Excellence for Neurodegenerative Diseases Research, Technion-Faculty of Medicine, Efron St PO Box 9697, Haifa 31096, Israel
    Neurosci Lett 355:169-72. 2004
  6. ncbi The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species
    Carolina A Braga
    Instituto de Bioquimica Medica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941 590, Brazil
    J Mol Biol 405:254-73. 2011
  7. ncbi Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial
    Shahin Akhondzadeh
    Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Avenue, Tehran 13334, Iran
    Prog Neuropsychopharmacol Biol Psychiatry 27:841-5. 2003
  8. ncbi Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial
    Mohammad Reza Mohammadi
    Department of Psychiatry, Tehran University of Medical Sciences, Psychiatry and Clinical Psychology Research Center, Roozbeh Hospital, Tehran, Iran
    J Child Adolesc Psychopharmacol 14:418-25. 2004
  9. ncbi Selegiline protects against recognition memory impairment induced by neonatal iron treatment
    Maria Noemia Martins de Lima
    , Instituto de Geriatria e Gerontologia, , , 90619-900 Porto Alegre, RS, Brazil
    Exp Neurol 196:177-83. 2005
  10. ncbi Increased cell-cell adhesion, a novel effect of R-(-)-deprenyl
    V Jenei
    Institute of Biomolecular Chemistry, Chemical Research Center, Hungarian Academy of Sciences, Budapest, Hungary
    J Neural Transm 112:1433-45. 2005

Research Grants

  1. CARDIOVASCULAR DISEASE PREVENTION TRAINING PROGRAM
    Stephen Fortmann; Fiscal Year: 2007
  2. RADIOTRACER RANDD IN NUCLEAR MEDICINE AND NEUROSCIENCES
    Joanna Fowler; Fiscal Year: 2000
  3. PARKINSON DISEASE NEUROPROTECTION CLINICAL TRIAL CENTER
    Bala Manyam; Fiscal Year: 2005
  4. Selegiline for Smoking Cessation
    MARC POTENZA; Fiscal Year: 2007
  5. Selegiline for Smoking Cessation
    Tony George; Fiscal Year: 2006
  6. Selegiline for Treatment of Cannabis Dependence
    BRENT MOORE; Fiscal Year: 2005
  7. NEUROLOGIC AIDS RESEARCH CONSORTIUM
    David Clifford; Fiscal Year: 2007
  8. Parkinson's Disease Neuroprotection Clinical Trial: Clinical Center
    Burton Scott; Fiscal Year: 2007
  9. Norepinephrine and Nerve Growth Factor in Heart Failure
    Chang Seng Liang; Fiscal Year: 2004
  10. Selegiline Patch for Treatment of Nicotine Dependence
    Joel Killen; Fiscal Year: 2007

Detail Information

Publications187 found, 100 shown here

  1. ncbi Neuroprotective actions of selegiline
    M Ebadi
    Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58203, USA
    J Neurosci Res 67:285-9. 2002
    b>Selegiline, a selective inhibitor of monoamine oxidase-B (MAO-B), was one of the first adjunct therapies in clinical neurology...
  2. ncbi Selegiline and oxidative stress in HIV-associated cognitive impairment
    G Schifitto
    University of Rochester, NY, USA
    Neurology 73:1975-81. 2009
    To assess the effectiveness of the selegiline transdermal system (STS) in reversing HIV-induced metabolic brain injury (as measured by proton magnetic resonance spectroscopy [MRS]) and in decreasing oxidative stress, measured by CSF ..
  3. ncbi A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition
    A Clarke
    Scherer DDS, Swindon, United Kingdom
    J Neural Transm 110:1257-71. 2003
    Three studies were performed using a fast dissolving formulation of selegiline hydrochloride designed for buccal absorption "Zydis Selegiline"...
  4. ncbi Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline
    A Kupsch
    Department of Neurology, Klinikum Grosshadern, Ludwig Maximilians University, and Institute of Physiology, Munchen, Federal Republic of Germany
    J Neural Transm 108:985-1009. 2001
    ..B (MAO-B) has been reported to be implicated in both MPTP-induced parkinsonism and Parkinson's disease, since selegiline (L-deprenyl), an irreversible MAO-B inhibitor, prevents MPTP-induced neurotoxicity in numerous species including ..
  5. ncbi Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline
    Orit Bar Am
    Eve Topf and US National Parkinson Foundation Center of Excellence for Neurodegenerative Diseases Research, Technion-Faculty of Medicine, Efron St PO Box 9697, Haifa 31096, Israel
    Neurosci Lett 355:169-72. 2004
    The anti-Parkinson selective irreversible monoamine oxidase B inhibitor drugs, rasagiline and selegiline, have been shown to possess neuroprotective activities in cell culture and in vivo models...
  6. ncbi The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species
    Carolina A Braga
    Instituto de Bioquimica Medica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941 590, Brazil
    J Mol Biol 405:254-73. 2011
    ..b>Selegiline (Sel) is a noncompetitive monoamino oxidase B inhibitor that has neuroprotective effects and has been ..
  7. ncbi Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial
    Shahin Akhondzadeh
    Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Avenue, Tehran 13334, Iran
    Prog Neuropsychopharmacol Biol Psychiatry 27:841-5. 2003
    ..b>Selegiline is a type B monoamine oxidase inhibitor (MAOI) that is metabolized to amphetamine and methamphetamine stimulant ..
  8. ncbi Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial
    Mohammad Reza Mohammadi
    Department of Psychiatry, Tehran University of Medical Sciences, Psychiatry and Clinical Psychology Research Center, Roozbeh Hospital, Tehran, Iran
    J Child Adolesc Psychopharmacol 14:418-25. 2004
    OBJECTIVES: The aim of this study was to examine the selegiline treatment compared to methylphenidate (MPH) in children and adolescents with attention deficit hyperactivity disorder (ADHD)...
  9. ncbi Selegiline protects against recognition memory impairment induced by neonatal iron treatment
    Maria Noemia Martins de Lima
    , Instituto de Geriatria e Gerontologia, , , 90619-900 Porto Alegre, RS, Brazil
    Exp Neurol 196:177-83. 2005
    ..The aim of the present study was to determine whether selegiline, a monoamine oxidase (MAO) inhibitor known for its neuroprotective properties, could protect rats against ..
  10. ncbi Increased cell-cell adhesion, a novel effect of R-(-)-deprenyl
    V Jenei
    Institute of Biomolecular Chemistry, Chemical Research Center, Hungarian Academy of Sciences, Budapest, Hungary
    J Neural Transm 112:1433-45. 2005
    ..The effect of R-(-)-deprenyl was not reversible during a 24-hour recovery period. In summary, we described a new, MAO-B independent effect of R-(-)-deprenyl on cell-cell adhesion which can contribute to its neuroprotective function...
  11. ncbi Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl]
    Sevil Yasar
    Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 317:387-94. 2006
    l-Deprenyl [selegiline, (R)-(-)-deprenyl] is a selective inhibitor of monoamine oxidase B (MAO-B) used in the treatment of Parkinson's disease and proposed as an antidepressant and an aid for cigarette-smoking cessation and treatment of ..
  12. ncbi (-)-D-Deprenyl attenuates apoptosis in experimental brain ischaemia
    L Simon
    National Institute of Psychiatry and Neurology, National Stroke Center, , H-1021, Budapest, Hungary
    Eur J Pharmacol 430:235-41. 2001
    ..D-Deprenyl treatment increased the number of GAP-43-positive cells. We conclude that (-)-D-deprenyl reduced the number of affected cells and induced neuronal plasticity...
  13. ncbi Selegiline potentiates the effects of EGb 761 in response to ischemic brain injury
    Y S Kwon
    Neurotoxicology Program, College of Pharmacy, Korea Institute of Drug Abuse, Kangwon National University, Chunchon 200-701, South Korea
    Neurochem Int 45:157-70. 2004
    We evaluated whether combined treatment with selegiline, a selective MAO-B inhibitor, and EGb 761, a standard extract of Ginkgo biloba, has synergistic effects against ischemic reperfusion injury (IRI) in gerbils...
  14. ncbi Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects
    Kelly E Lyons
    University of Kansas Medical Center, Kansas City, KS 66160, USA
    Clin Neuropharmacol 33:5-10. 2010
    To determine whether adding orally disintegrating selegiline (ODS) while decreasing dopamine agonist (DA) dosages would reduce DA-related adverse effects (AEs) of excessive daytime sleepiness (EDS), pedal edema, hallucinations, and ..
  15. ncbi The multiple actions of selegiline
    Manuchair Ebadi
    Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota, School of Medicine and Health Sciences, P.O. Box 9037, 501 North Columbia Road, Grand Forks, ND 58203, USA
    Proc West Pharmacol Soc 45:39-41. 2002
  16. ncbi Low dose (-)deprenyl is cytoprotective: it maintains mitochondrial membrane potential and eliminates oxygen radicals
    L Simon
    National Institute of Psychiatry and Neurology, National Stroke Center, Department of Vascular Neurology, Semmelweis University, Budapest H 1021 Hungary
    Life Sci 78:225-31. 2005
    ....
  17. ncbi Orally disintegrating selegiline for the treatment of Parkinson's disease
    Matthias Lohle
    Technische Universitat Dresden, Department of Neurology, Fetscherstrasse 74, 01307 Dresden, Germany
    Expert Opin Pharmacother 9:2881-91. 2008
    The selective monoamine oxidase type B inhibitor selegiline is commonly administered as medical treatment to patients suffering from Parkinson's disease...
  18. ncbi Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration
    Wen Zhu
    Department of Neurology, The 1st Affiliated Hospital of Sun Yat sen University, Guangzhou, China
    J Neurochem 105:1970-8. 2008
    ..Rasagiline and selegiline are selective and irreversible monoamine oxidase-B inhibitors that possess significant protective properties on ..
  19. ncbi Freezing of gait in PD: prospective assessment in the DATATOP cohort
    N Giladi
    Movement Disorders Division, Department of Neurology, Columbia-Presbyterian Medical Center, New York, NY, USA
    Neurology 56:1712-21. 2001
    ..Deprenyl, in the absence of L-dopa, was found to be an effective prophylactic treatment and should be considered for patients with PD who have an onset of gait difficulty...
  20. ncbi Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort
    C Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada M5T 2S8
    Neurology 64:87-93. 2005
    ..To investigate predictors of survival in Parkinson disease (PD)...
  21. ncbi Transdermal selegiline: targeted effects on monoamine oxidases in the brain
    Lynn Wecker
    Department of Pharmacology and Therapeutics, University of South Florida College of Medicine, Tampa, Florida 33612-4799, USA
    Biol Psychiatry 54:1099-104. 2003
    ..These studies determined whether the transdermal administration of selegiline has differential effects on MAOs in brain versus the gastrointestinal system...
  22. ncbi Transdermal selegiline and intravenous cocaine: safety and interactions
    Elisabeth J Houtsmuller
    Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Bayview Medical Center, 5510 Nathan Shock Drive, Baltimore, MD 21224 6823, USA
    Psychopharmacology (Berl) 172:31-40. 2004
    ..b>Selegiline, a selective monoamine oxidase B inhibitor, indirectly modulates dopamine levels, and research suggests ..
  23. ncbi A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation
    R Biberman
    Division of Health, Maccabi Health Care Services, Sackler Medical Faculty, Tel Aviv University, Israel
    Addiction 98:1403-7. 2003
    To compare the effect of oral selegiline plus nicotine patch with placebo plus nicotine patch on smoking cessation rates.
  24. ncbi Effects of (-)deprenyl (selegiline) on acetylcholinesterase and Na(+),K(+)-ATPase activities in adult rat whole brain
    Charalambos Antoniades
    Department of Experimental Physiology, Medical School, University of Athens, P.O. Box 65257, GR-154 01 Athens, Greece
    Pharmacol Res 46:165-9. 2002
    ..We conclude that (-)deprenyl is an indirect AChE inhibitor and Na(+),K(+)-ATPase stimulator in the rat brain (in vitro)...
  25. ncbi Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man
    M Katagi
    Forensic Science Laboratory, Osaka Prefectural Police HQ, 1 3 18, Hommachi, Chuoku, Osaka 541 0053, Japan
    Xenobiotica 32:823-31. 2002
    1. The metabolism of selegiline (SG) has been studied by investigating the time-course of urinary excretion of SG and its metabolites using high-performance liquid chromatography-electrospray ionization mass spectrometry (LC-ESI MS) in ..
  26. ncbi Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients
    J Alexander Bodkin
    McLean Hospital, 115 Mill St. Belmont, MA 02478, USA
    Am J Psychiatry 159:1869-75. 2002
    OBJECTIVE: The authors investigated the efficacy and safety of transdermal selegiline in adult outpatients with major depressive disorder...
  27. ncbi A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation
    Tony P George
    Program for Research in Smokers with Mental Illness (PRISM, New Haven, Connecticut 06519, USA
    Biol Psychiatry 53:136-43. 2003
    ..to be involved in nicotine dependence, we studied the safety and efficacy of the monoamine oxidase B inhibitor selegiline hydrochloride compared with placebo for smoking cessation in nicotine-dependent cigarette smokers...
  28. ncbi Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine
    Wynne K Schiffer
    Department of Neurobiology and Behavior, Stony Brook University, Stony Brook, New York 11794, USA
    Synapse 48:35-8. 2003
    b>Selegiline has been proposed as a treatment for cocaine addiction and studies in humans suggest that it attenuates cocaine's reinforcing effects...
  29. ncbi Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues
    Michael Mawhinney
    Department of Pharmacology, West Virginia University School of Medicine, Morgantown, WV 26506, USA
    J Pharm Pharmacol 55:27-34. 2003
    b>Selegiline has been formulated in an acrylic polymer adhesive mixture to be employed as a constant release topical patch for daily transdermal administration...
  30. ncbi A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, USA
    J Clin Psychiatry 64:208-14. 2003
    The monoamine oxidase (MAO) inhibitor selegiline has demonstrated antidepressant efficacy superior to placebo...
  31. ncbi Selegiline long-term effects on brain acetylcholinesterase, (Na+,K+)-ATPase activities, antioxidant status and learning performance of aged rats
    Haris Carageorgiou
    Department of Experimental Pharmacology, Medical School, University of Athens, Athens, Greece
    Pharmacol Res 48:245-51. 2003
    The aim of this study was to investigate the effects of selegiline ((-)deprenyl), an irreversible inhibitor of monoaminoxidase-B (MAO-B): (a) on brain acetylcholinesterase (AChE), (Na(+),K(+))-ATPase and Mg(2+)-ATPase activities; (b) ..
  32. ncbi Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems
    Jarmo S Salonen
    Orion Pharma Preclinical and Clinical R and D, Turku, Finland
    Drug Metab Dispos 31:1093-102. 2003
    b>Selegiline was used as a model compound in a project aimed at comparing, evaluating, and integrating different in vitro approaches for the prediction of cytochrome p450 (p450)-catalyzed hepatic drug metabolism in humans (EUROCYP)...
  33. ncbi A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition
    A Clarke
    Scherer DDS, Swindon, United Kingdom
    J Neural Transm 110:1241-55. 2003
    ..studies were conducted in healthy volunteers to compare the pharmacokinetic and pharmacodynamic profiles of selegiline hydrochloride in a new formulation designed for buccal absorption "Zydis Selegiline" (1...
  34. ncbi Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline
    Zaid A Abassi
    Department of Physiology and Biophysics, Technion Rappaport Faculty of Medicine and Rappaport Family Institute for Research in the Medical Sciences, Technion, Haifa, Israel
    Br J Pharmacol 143:371-8. 2004
    b>Selegiline is used for treating Parkinson's disease...
  35. ncbi Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice
    Eric C K Siu
    Department of Pharmacology, University of Toronto, 1 King s College Circle, Room 4326, Toronto, Ontario, Canada
    J Pharmacol Exp Ther 324:992-9. 2008
    b>Selegiline (l-deprenyl) is in clinical treatment trials as a potential smoking cessation drug. We investigated the affect of selegiline and its metabolites on nicotine metabolism...
  36. ncbi Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers
    Albert J Azzaro
    Somerset Pharmaceuticals, Inc
    J Clin Pharmacol 47:978-90. 2007
    b>Selegiline transdermal system is a recently approved monoamine oxidase inhibitor antidepressant...
  37. ncbi Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications
    Albert J Azzaro
    Chief Scientific Officer, Somerset Pharmaceuticals, Inc, Rocky Point Center, 3030 North Rocky Point Drive, Suite 250, Tampa, FL 33607, USA
    J Clin Pharmacol 47:146-58. 2007
    b>Selegiline transdermal system (STS) is a recently approved monoamine oxidase inhibitor antidepressant...
  38. ncbi The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30
    Moussa B H Youdim
    Eve Topf Centres of Excellence for Neurodegenerative Diseases Research, Technion Rappaport Family Faculty of Medicine and Department of Pharmacology, Haifa, Israel
    Curr Alzheimer Res 3:541-50. 2006
    ..has its origin in the anti Parkinson action of the selective monoamine oxidase (MAO) B inhibitor, l-deprenyl (selegiline ), a failed anti depressant in 1975...
  39. ncbi Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial
    Alan D Feiger
    Department of Psychiatry, University of Colorado School of Medicine, Denver, CO, USA
    J Clin Psychiatry 67:1354-61. 2006
    This study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder (MDD).
  40. ncbi Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects
    Albert J Azzaro
    Somerset Pharmaceuticals, Inc, Tampa, Florida, USA
    J Clin Pharmacol 46:933-44. 2006
    The oral tyramine pressor test was administered to healthy males during treatment with a selegiline transdermal system (STS; 6 mg/24 h)...
  41. ncbi Amphetamine-induced locomotor activity is reduced in mice following MPTP treatment but not following selegiline/MPTP treatment
    Brian D West
    Neuroscience Drug Discovery, Merck Research Laboratories, P.O. Box 4, WP44E-200, West Point, PA 19486, USA
    Pharmacol Biochem Behav 84:158-61. 2006
    ..Further, the potential for use of this endpoint to evaluate putative therapeutics is exemplified by the amelioration of these effects following pre-treatment with the MAO-B inhibitor selegiline.
  42. ncbi Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence
    Ahmed Elkashef
    National Institute on Drug Abuse NIDA, Division of Pharmacotherapies and Medical Consequences of Drug Abuse DPMCDA, MSC 9551 Bethesda, MD 20892, USA
    Drug Alcohol Depend 85:191-7. 2006
    ..b>Selegiline is an irreversible selective inhibitor of monoamine oxidase type B (MAO-B) which may affect cocaine addiction ..
  43. ncbi Selegiline slows the progression of the symptoms of Parkinson disease
    S Palhagen
    Department of Neurology, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Neurology 66:1200-6. 2006
    To study the long-term effects of selegiline in monotherapy and in combination with levodopa in the early phase of Parkinson disease (PD).
  44. ncbi Clomipramine and selegiline: do they influence impulse control?
    B Bert
    Institute of Pharmacology and Toxicology, School of Veterinary Medicine, Freie Universitat Berlin, Berlin, Germany
    J Vet Pharmacol Ther 29:41-7. 2006
    ..The reduction of these undesirable actions is the focus of behaviour therapy. Clomipramine and selegiline have been approved for the treatment of separation anxiety in dogs, but there are anecdotal reports that they ..
  45. ncbi A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at the University of California at Los Angeles, USA
    Pharmacol Biochem Behav 82:704-11. 2005
    b>Selegiline (L-deprenyl) is a selective irreversible monoamine oxidase B inhibitor shown to be effective in the treatment of Parkinson's and Alzheimer's diseases...
  46. ncbi Antidepressant-like effects of selegiline in the forced swim test
    Seiichiro Shimazu
    Research Institute, Fujimoto Pharmaceutical Corporation, 1 3 40 Nishiotsuka, Matsubara, Osaka 580 0011, Japan
    Eur Neuropsychopharmacol 15:563-71. 2005
    Although selegiline, a monoamine oxidase (MAO)-B inhibitor, is reported to exert antidepressant effects in depressant patients, evidence in rodents for effects of selegiline is quite limited...
  47. ncbi Effects of selegiline alone or with donepezil on memory impairment in rats
    Kazue Takahata
    Research Institute, Fujimoto Pharmaceutical Corporation, 1-3-40 Nishiotsuka, Matsubara, Osaka 580-0011, Japan
    Eur J Pharmacol 518:140-4. 2005
    b>Selegiline, a monoamine oxidase-B inhibitor, is reported to improve memory and learning in dementia of Alzheimer's type. However, only a few studies have reported its use in animal models...
  48. ncbi A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment
    G Schifitto
    Department of Neurology, Movement and Inherited Neurologic Disorders, Clinical Trials Coordination Center, 1351 Mount Hope Avenue, Suite 223, Rochester, NY 14620, USA
    Neurology 69:1314-21. 2007
    ..b>Selegiline is an MAO-B inhibitor with antioxidant and neurotrophic properties...
  49. ncbi Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline
    Keiko Kamakura
    Third Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
    Parkinsonism Relat Disord 10:235-42. 2004
    b>Selegiline protects nigral dopaminergic neurons and is recommended for the treatment of patients in the early stage of Parkinson's disease (PD)...
  50. ncbi Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus
    N Hamaue
    The Research Institute of Personalized Health Sciences, Health Sciences University of Hokkaido, 061-0293 Ishikari-Tobetsu, Japan
    Neurotoxicology 25:205-13. 2004
    ..b>Selegiline [(-)-deprenil] was developed as a MAO-B inhibitor more than 30 years ago and widely used in the treatment of ..
  51. ncbi Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis
    Shawna Tazik
    Division of Neurobiology and Behavioral Research, Department of Psychiatry and Human Behavior G 109, University of Mississippi Medical Center, 2500N State Street, Jackson, MS 39216, USA
    Neurotox Res 15:284-90. 2009
    ..In this study, we have compared the ability of rasagiline (Azilect) and its main metabolite, R-aminoindan with selegiline (Deprenyl) in prevention of dexamethasone-induced brain cell death employing human neuroblastoma SH-SY5Y cells ..
  52. ncbi Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
    Ira Shoulson
    University of Rochester Medical Center, Rochester, NY 14620, USA
    Ann Neurol 51:604-12. 2002
    Deprenyl (selegiline) delays the need for levodopa therapy in patients with early Parkinson's disease, but the long-term benefits of this treatment remain unclear...
  53. ncbi Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation
    Rita Moretti
    Int J Geriatr Psychiatry 17:391-2. 2002
  54. ncbi Clinical pharmacokinetics and pharmacodynamics of selegiline. An update
    I Mahmood
    Division of Pharmaceutical Evaluation I, Food and Drug Administration, Rockville, Maryland, USA
    Clin Pharmacokinet 33:91-102. 1997
    b>Selegiline is a selective inhibitor of monoamine oxidase-B (MAO-B) at a dose of 10 mg/day and is given to patients with Parkinson's disease as an adjunct to levodopa therapy...
  55. ncbi Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study
    A Negrotti
    Istituto di Neurologia, , Italy
    J Neural Transm 108:215-9. 2001
    Following a two-months of placebo-controlled withdrawal, the MAO-B inhibitor selegiline was found to maintain a long term significant mild to moderate symptomatic effect on bradykinesia and tremor at rest in nine patients with Parkinson's ..
  56. ncbi Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group
    V Filip
    Department of Psychiatry, Comenius University, Bratislava, Slovak Republic
    J Psychiatry Neurosci 24:234-43. 1999
    To evaluate the efficacy and adverse effects of the type B monoamine oxidase inhibitor selegiline (also known as I-deprenyl) in the treatment of Alzheimer's disease.
  57. ncbi Selegiline completely restores choline acetyltransferase activity deficits in simian immunodeficiency infection
    E Koutsilieri
    Clinical Neurochemistry, Department of Psychiatry, University of Wurzburg, Fuchsleinstr 15, 97080, Wurzburg, Germany
    Eur J Pharmacol 411:R1-R2. 2001
    ..We report now that selegiline, completely restores the reduced choline acetyltransferase activity which encourages for a meaningful anti-..
  58. ncbi The influence of metabolism on the MAO-B inhibitory potency of selegiline
    D Haberle
    Department of Pharmacodynamics Semmelweis University, H 1445 Budapest, Hungary
    Curr Med Chem 9:47-51. 2002
    Deprenyl (selegiline), a propargylamine derivative of methylamphetamine, is a potent, irreversible inhibitor of monoamine-oxidase type B (MAO-B). The MAO-B inhibitory effects of various doses (0.1-0.25-0...
  59. ncbi The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials
    G K Wilcock
    Department of Care of the Elderly, University of Bristol, UK
    Int J Geriatr Psychiatry 17:175-83. 2002
    To evaluate the effect of selegiline in the treatment of patients with Alzheimer's disease, in terms of cognitive performance, functional ability, emotional state (including behaviour and mood) and global response...
  60. ncbi Chronic daily administration of selegiline and EGb 761 increases brain's resistance to ischemia in mice
    I Unal
    Department of Neurology, Faculty of Medicine and Institute of Neurological Sciences and Psychiatry, Hacettepe University, 06100, Ankara, Turkey
    Brain Res 917:174-81. 2001
    ..Acute administration of selegiline and EGb 761 have been shown to have anti-apoptotic and neuroprotective effects in experimental ischemia...
  61. ncbi Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study
    N Sacktor
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Neurology 54:233-5. 2000
    ..a pilot randomized, double-blind, placebo-controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated ..
  62. ncbi CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes
    M Hidestrand
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
    Drug Metab Dispos 29:1480-4. 2001
    In view of conflicting data in the literature regarding the enzyme(s) responsible for metabolism of selegiline, a drug used in the treatment of Parkinson's disease, investigations were carried out in vitro using the human cytochrome P450 ..
  63. ncbi Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes
    P Taavitsainen
    Department of Pharmacology and Toxicology, University of Oulu, Finland
    Pharmacol Toxicol 86:215-21. 2000
    Although being a drug therapeutically used for a long time, the enzymatic metabolism of selegiline has not been adequately studied...
  64. ncbi Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour
    Lawrence F Blob
    Somerset Pharmaceuticals, Tampa, FL 33607, USA
    CNS Spectr 12:25-34. 2007
    ..A selegiline transdermal system (STS) was developed to provide antidepressant concentrations of selegiline in the brain, ..
  65. ncbi Selegiline in narcolepsy
    S E Roselaar
    University Department of Neurology, King's College School of Medicine, London, England
    Sleep 10:491-5. 1987
    We examined the effect of the specific monoamine oxidase-B (MAO-B) inhibitor selegiline (deprenyl, Eldepryl), 20-30 mg p.o. daily, in 21 subjects with the narcoleptic syndrome for 4 weeks...
  66. ncbi Toxicokinetic evaluation of a selegiline transdermal system in the dog
    J S Barrett
    Somerset Pharmaceuticals, Tampa, FL, USA
    Biopharm Drug Dispos 18:165-84. 1997
    The toxicology and toxicokinetics of a selegiline transdermal system (STS) were evaluated in a 3 month dog study of daily 24 h applications of placebo 4, 8, or 12 STSs in 32 male and 32 female beagle dogs...
  67. ncbi Selegiline's neuroprotective capacity revisited
    P Riederer
    Clinical Neurochemistry, Clinic and Policlinic for Psychiatry and Psychotherapy, University of Wuerzburg, Germany
    J Neural Transm 110:1273-8. 2003
  68. ncbi Reexamination of the TEMPO Study
    Clifford W Shults
    Arch Neurol 62:1320; author reply 1321. 2005
  69. ncbi [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl]
    Melinda Pálfi
    Magyar Tudományos Akadémia, Neurokémiai Kutatócsoport, Budapest
    Orv Hetil 147:1251-7. 2006
    ..Data are accumulating about the relationship of these enzymes and propargyl compounds, but the real significance of this issue will only be established by future research...
  70. ncbi Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons
    Enid T McKinley
    Zygogen, 520 Kell Hall, 24 Peachtree Center Avenue, Atlanta, GA 30303, USA
    Brain Res Mol Brain Res 141:128-37. 2005
    ..Effects on swimming behavior and touch response that result from MPTP damage are partially ameliorated by both l-deprenyl and DAT knockdown...
  71. ncbi [Role of R-(-)-deprenyl in adhesion of neuronal and non-neuronal cells]
    Veronika Jenei
    Magyar Tudományos Akadémia, Kémiai Kutatóközpont, Biomolekuláris Kémiai Intézet, Budapest
    Orv Hetil 146:601-6. 2005
    ..The authors' results with S-(+)-deprenyl suggest that the sterical structure of the drug is an important factor of the observed effect, which is probably a consequence of an irreversible change in the cells...
  72. ncbi Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease
    Jack J Chen
    Movement Disorders Center, Loma Linda University, Loma Linda, CA, USA
    J Clin Pharmacol 45:878-94. 2005
    ..Rasagiline completely and selectively inhibits MAO-B with a potency 5 to 10 times greater than selegiline. Unlike the prototype propargylamine selegiline, which is metabolized to amphetamine derivatives, rasagiline is ..
  73. ncbi A novel formulation of selegiline for the treatment of Parkinson's disease
    James W Tetrud
    The Parkinson's Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
    Neurology 63:S2-6. 2004
  74. ncbi Clinical trials of neuroprotection for Parkinson's disease
    Peter A LeWitt
    Departments of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, The William Beaumont Hospital Research Institute, Royal Oak, Michigan, USA
    Neurology 63:S23-31. 2004
  75. ncbi A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease
    Moussa B H Youdim
    Department of Pharmacology, Technion-Bruce Rappaport Faculty of Medicine, Eve Topf and NPF Neurodegenerative Diseases Centers, Rappaport Family Research Institute, Haifa, Israel
    Neurology 63:S32-5. 2004
  76. ncbi Other pharmacological treatments for motor complications and dyskinesias
    Cheryl Waters
    Division of Movement Disorders, Department of Neurology, Columbia University, 710 West 168th Street, New York, NY 10032, USA
    Mov Disord 20:S38-44. 2005
    ..Patients may also suffer from dyskinesias. Dyskinesias can be treated with small doses of liquefied levodopa-carbidopa, amantadine, and clozapine, an atypical neuroleptic...
  77. ncbi Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease
    Elisenda Sanz
    Departament de Bioquimca i Biologia Molecular, Facultad de Medicina, Institut de Neurociencies, , Campus Universitari de Bellaterra, Barcelona, Spain
    Med Sci Monit 10:BR477-84. 2004
    ..The antioxidant properties of PF 9601 N would explain its neuroprotective effect observed in SHSY5Y cells lesioned with dopamine...
  78. ncbi Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
    Christopher G Goetz
    Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 20:523-39. 2005
    ..b>Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias. Other designations did not change...
  79. ncbi Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytriptamine turnover in the striatum
    N Kitanaka
    Department of Pharmacology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan
    Neuroscience 130:295-308. 2005
    ..5-2 mg/kg (i.p.). In contrast, single or repeated pretreatment of selegiline (0.3 mg/kg, s.c.), a MAO-B inhibitor, had no effect on METH-induced hyperlocomotion...
  80. ncbi Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice
    Atsushi Mori
    Research Unit for Neurological Diseases, Second Institute of New Drug Discovery, Otsuka Pharmaceutical Co, Ltd, Tokushima-city, Tokushima 771-0192, Japan
    Neurosci Res 51:265-74. 2005
    ..We concluded that the increase in immobility time in the TST was induced by the nigrostriatal dopaminergic degeneration and was thought to be a consequence of motor dysfunction in this mouse model of PD...
  81. ncbi [Neuroprotective and neurorestorative therapy in Parkinson's disease]
    F J Jimenez-Jimenez
    Departamento de Neurologia, Hospital Universitario Principe de Asturias, Alcalúa de Henares, Madrid, Espana
    Rev Neurol 25:S185-93. 1997
    ..This article reviews the current knowledge on the possible neuroprotective and restorative treatments in Parkinson's disease...
  82. ncbi Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors
    Claire Henchcliffe
    Weill Medical College of Cornell University, Department of Neurology and Neuroscience, 428 East 72, Street, Suite 400, NY 10021, USA
    Expert Rev Neurother 5:811-21. 2005
    ..b>Selegiline is currently the most widely used monoamine oxidase-B inhibitor for Parkinson's disease, but has a low and ..
  83. ncbi Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant
    Mona Seif-el-Nasr
    Department of Pharmacology, Faculty of Pharmacy, Cairo University, Cairo, Egypt
    Arzneimittelforschung 58:160-7. 2008
    ....
  84. ncbi Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease
    M B H Youdim
    Department of Pharmacology, Technion Faculty of Medicine, Eve Topf and US National Parkinson Foundation Centers for Neurodegenerative Diseases, The B Rappaport Family Medical Research Institute, 31096 Haifa, Israel
    Parkinsonism Relat Disord 8:247-53. 2002
    Rats were injected intraperitoneally with varying doses of l-deprenyl (selegiline) followed 2h later by 30 mg kg(-1) 2-phenylethylamine (PEA), administered in the same way, and the stereotypic behavioural response elicited was assessed...
  85. ncbi Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells
    Thomas Muller
    Department of Neurology, St Josef Hospital, University of Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Neurol Res 30:417-9. 2008
    Long-term administration of the monoamine oxidase (MAO)-B inhibitor selegiline may reduce neuronal death based on preclinical findings and reduce progression of chronic neurodegeneration due to outcomes of long-term clinical trials in ..
  86. ncbi Monoamine oxidase-B inhibition in the treatment of Parkinson's disease
    Hubert H Fernandez
    Movement Disorders Center, University of Florida, McKnight Brain Institute, Gainesville, FL 32610, USA
    Pharmacotherapy 27:174S-185S. 2007
    ..The two available MAO-B inhibitors approved for use in the United States, rasagiline and selegiline, each provide symptomatic relief as monotherapy and as adjunctive therapy, and have shown potential disease-..
  87. ncbi Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease
    Jack J Chen
    Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
    Clin Ther 29:1825-49. 2007
    ..Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain MAO-B and is specifically designed for the treatment of Parkinson's disease (PD)...
  88. ncbi In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human
    David A Erickson
    Department of Drug Metabolism, Covance Laboratories Inc, Madison, WI, USA
    Drug Metab Dispos 35:2232-41. 2007
    ..inhibited in human hepatic microsomes and mitochondria by the monoamine oxidase (MAO)-B-specific inhibitor selegiline. Clorgyline, a specific inhibitor of MAO-A, was less effective in inhibiting M12 formation...
  89. ncbi Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?
    Glen B Baker
    J Psychiatry Neurosci 32:313-5. 2007
  90. ncbi Rasagiline as a therapy for Parkinson's disease (PD)
    Neal Hermanowicz
    Am J Geriatr Pharmacother 5:174-5; author reply 175-6. 2007
  91. ncbi Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors
    Jack J Chen
    Movement Disorders Center, Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
    Drugs Aging 24:663-80. 2007
    ..Monoamine oxidase type B (MAO-B) inhibitors can be used across the spectrum of disease severity, but selegiline (deprenyl), the prototype in this class, is characterised by low and erratic bioavailability of the parent drug ..
  92. ncbi Monamine oxidase inhibitors: current and emerging agents for Parkinson disease
    Hubert H Fernandez
    Movement Disorders Center, Department of Neurology, McKnight Brain Institute University of Florida, Gainesville, FL 32610, USA
    Clin Neuropharmacol 30:150-68. 2007
    ..Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, for the symptomatic treatment of Parkinson disease (PD)...
  93. ncbi Antioxidant effects of selegiline in oxidative stress induced by iron neonatal treatment in rats
    Patricia Budni
    Laboratório de Fisiopatologia Experimental, Universidade do Extremo Sul Catarinense, Criciuma, Brazil
    Neurochem Res 32:965-72. 2007
    ..The aim of the present study was to evaluate the possible protective effect of selegiline, a monoamino-oxidase B (MAO-B) inhibitor used in pharmacotherapy of Parkinson's disease, against iron-induced ..
  94. ncbi Monoamine oxidase inhibitory coumarins from the aerial parts of Dictamnus albus
    Seon Hwa Jeong
    College of Pharmacy, Chungbuk National University, Cheongju 361 763, Korea
    Arch Pharm Res 29:1119-24. 2006
    ..5 and 0.6 microM, respectively) compared to MAO-A (IC50 1.3 and 34.6 microM, respectively). According to kinetic analyses derived by Lineweaver-Burk reciprocal plots, compounds 1 and 2 exhibited a competitive inhibition to MAO-B...
  95. ncbi Effects of subchronic treatment with selegiline on L-DOPA-induced increase in extracellular dopamine level in rat striatum
    Kouichi Adachi
    Department of Neurology, Wakayama Medical University, Wakayama, Japan
    J Pharmacol Sci 101:286-92. 2006
    b>Selegiline is used an adjunct to L-DOPA therapy. We investigated extracellular striatal dopamine (DA) level in awake rats treated with L-DOPA and/or selegiline using a microdialysis method. Rats given 10 mg/kg, i.p...
  96. ncbi (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity
    Matilde Yáñez
    Departamento de Farmacologia, Facultad de Farmacia, Universidad de Santiago de Compostela, Campus Universitario Sur, E 15782 Santiago de Compostela La Coruña, Spain
    Eur J Pharmacol 542:54-60. 2006
    ....
  97. ncbi High-throughput screening for monoamine oxidase-A and monoamine oxidase-B inhibitors using one-step fluorescence assay
    Hong-mei Guang
    Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China
    Acta Pharmacol Sin 27:760-6. 2006
    ..71+/-0.03 and 0.75+/-0.03 in MAO-A-inhibitor and MAO-B-inhibitor HTS system, respectively. CONCLUSION: The established assays can be well applied to MAO-A and MAO-B inhibitor screening with high quality, precision and reproducibility...
  98. ncbi Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
    Moussa B H Youdim
    Department of Pharmacology and Technion Bruce Rappaport Faculty of Medicine, Eve Topf and NPF Centers of Excellence for Neurodegenerative Diseases Research and Teaching, Haifa, Israel
    Br J Pharmacol 147:S287-96. 2006
    ..These aspects of MAO and its inhibition and some indication of how this important area of pharmacology and therapeutics might develop in the future are summarized in this review...
  99. ncbi [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508]
    Ildiko Miklya
    Semmelweis Egyetem, AOK, Farmakológiai és Farmakoterápiás Intézet, Budapest
    Neuropsychopharmacol Hung 10:15-22. 2008
    ..Thus, rasagiline can not be a substitute for (-)-deprenyl in therapy...
  100. ncbi Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease
    Peter Jenner
    Neurodegenerative Diseases Research Centre, Guy's, King's and St Thomas' School of Biomedical Sciences, King's College, London, United Kingdom
    Neurology 63:S13-22. 2004
  101. ncbi [Parkinson's disease]
    K Miyoshi
    Hyogo Institute for Aging Brain and Cognitive Disorders
    Nippon Rinsho 59:1570-3. 2001
    ..Serotonin reuptake inhibitors and selegiline are recommended for the treatment of depression in parkinsonian patients.

Research Grants76

  1. CARDIOVASCULAR DISEASE PREVENTION TRAINING PROGRAM
    Stephen Fortmann; Fiscal Year: 2007
    ..and improving quality of life in persons over 65, behavioral maintenance treatment in smoking cessation, selegiline for smoking cessation, retail tobacco marketing effects on adolescent smoking initiation, pro- and anti-smoking ..
  2. RADIOTRACER RANDD IN NUCLEAR MEDICINE AND NEUROSCIENCES
    Joanna Fowler; Fiscal Year: 2000
    ....
  3. PARKINSON DISEASE NEUROPROTECTION CLINICAL TRIAL CENTER
    Bala Manyam; Fiscal Year: 2005
    ..disease, not yet requiring symptomatic treatment and unexposed to prior treatment with levodopa/dopamine agonist/selegiline (within four months). 3)...
  4. Selegiline for Smoking Cessation
    MARC POTENZA; Fiscal Year: 2007
    ..In support of this hypothesis, in preliminary studies, we have shown that the selective MAO-B inhibitor selegiline hydrochloride (10 mg/day) significantly increases smoking abstinence rates compared to placebo...
  5. Selegiline for Smoking Cessation
    Tony George; Fiscal Year: 2006
    ..In support of this hypothesis, in preliminary studies, we have shown that the selective MAO-B inhibitor selegiline hydrochloride (10 mg/day) significantly increases smoking abstinence rates compared to placebo...
  6. Selegiline for Treatment of Cannabis Dependence
    BRENT MOORE; Fiscal Year: 2005
    ..b>Selegiline, a monoamine oxidase-B inhibitor, increases dopamine activity in mesolimbic and other brain regions involved in ..
  7. NEUROLOGIC AIDS RESEARCH CONSORTIUM
    David Clifford; Fiscal Year: 2007
    ..Complete and analyze A5090 testing the safety and efficacy of transdermal selegiline for HIV- associated motor cognitive disorder; 2...
  8. Parkinson's Disease Neuroprotection Clinical Trial: Clinical Center
    Burton Scott; Fiscal Year: 2007
    ..At this time, only selegiline (Eldrepyl), a selective monoamine oxidase-B (MAO-B) inhibitor has been approved by the US Food & Drug ..
  9. Norepinephrine and Nerve Growth Factor in Heart Failure
    Chang Seng Liang; Fiscal Year: 2004
    ..Superoxide dismutase and selegiline, which have been shown to prevent cardiac sympathetic nerve abnormalities in heart failure, will be used to ..
  10. Selegiline Patch for Treatment of Nicotine Dependence
    Joel Killen; Fiscal Year: 2007
    ..Primary aim: To conduct the first randomized controlled trial of the efficacy of selegiline patch (STS) for the treatment of nicotine dependence...